NCT02593318View on ClinicalTrials.gov

Trial of Oxaloacetate in Alzheimer's Disease (TOAD)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Alzheimer's Disease (AD)
Interventions
DRUG

Oxaloacetate (OAA) 1g

Pills to be taken orally in 500mg dose two times per day

DRUG

Oxaloacetate (OAA) 2g

Pills to be taken orally in 1000mg dose two times per day.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

Russell Swerdlow

OTHER

NCT02593318 - Trial of Oxaloacetate in Alzheimer's Disease (TOAD) | Biotech Hunter | Biotech Hunter